Chicago: Two experimental drugs designed to block genes tied to advanced melanoma have shown promise in preventing the lethal skin cancer from worsening longer than chemotherapy, a new research has claimed.Both the drugs, trametinib and dabrafenib, from a British farmaceutical major were tested in advanced melanoma patients in trials, and the results were are presented at a meeting in Chicago of the American Society of Clinical Oncology.It was found that about 80 per cent of patients with BRAF-mutated tumours given trametinib were alive after six months, compared with 67 per cent on chemotherapy used as a standard treatment.Separately, GlaxoSmithKline`s dabrafenib delayed the disease progression by 5.1 months, compared to 2.7 months for chemotherapy, said Dr Caroline Robert, lead investigator of the study."In melanoma, we are living something incredible," Dr Robert, head of dermatology at the Institut Gustave Roussy in Villejuif, France, was quoted as saying by the New York Times.
Smriti Irani files nomination from Amethi
Srinivasan should be kept out of BCCI affairs: SC
61st National Film Awards announced
Ananth Kumar calls Congress a non-performer across India